Exploring the effect of formulation parameters on the particle size of carboxymethyl chitosan nanoparticles prepared via reverse micellar crosslinking

Sheikholeslami, Zeinab Sadat; Salimi-Kenari, Hamed; Imani, Mohammad; Atai, Mohammad; Nodehi, Azizollah

doi:10.1080/02652048.2017.1321047

Cited by 20 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The organic solvent is evaporated results in formation of transparent dry mass, then the latter is dispersed in water and then a suitable salt is added for precipitating the surfactant [115,116]. A very narrow size range nanoparticle is seen and organic solvents are used [117].…”

Section: Preparation Of Chitosan Nanoparticlesmentioning

confidence: 99%

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

et al. 2017

View full text Add to dashboard Cite

The focus of this review is to provide an overview of the chitosan based nanoparticles for various non-parenteral applications and also to put a spotlight on current research including sustained release and mucoadhesive chitosan dosage forms. Chitosan is a biodegradable, biocompatible polymer regarded as safe for human dietary use and approved for wound dressing applications. Chitosan has been used as a carrier in polymeric nanoparticles for drug delivery through various routes of administration. Chitosan has chemical functional groups that can be modified to achieve specific goals, making it a polymer with a tremendous range of potential applications. Nanoparticles (NP) prepared with chitosan and chitosan derivatives typically possess a positive surface charge and mucoadhesive properties such that can adhere to mucus membranes and release the drug payload in a sustained release manner. Chitosan-based NP have various applications in non-parenteral drug delivery for the treatment of cancer, gastrointestinal diseases, pulmonary diseases, drug delivery to the brain and ocular infections which will be exemplified in this review. Chitosan shows low toxicity both in vitro and some in vivo models. This review explores recent research on chitosan based NP for non-parenteral drug delivery, chitosan properties, modification, toxicity, pharmacokinetics and preclinical studies.

show abstract

Section: Preparation Of Chitosan Nanoparticlesmentioning

confidence: 99%

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Over the last few years, many attempts have been made to develop synthetic methods for CS-based particles, such as ionic gelation [ 44 , 45 , 46 ], polyelectrolyte complexation [ 47 , 48 , 49 ], emulsion solvent diffusion [ 50 , 51 ], emulsion crosslinking [ 52 , 53 ], spray drying [ 54 , 55 ], supercritical fluid drying [ 56 ], electrospraying [ 57 ], emulsion droplet coalescence [ 58 ], reverse micellar/emulsion methods [ 59 , 60 ] and sieving methods [ 61 ].…”

Section: Preparation Methods For Chitosan-based Network and Particula...mentioning

confidence: 99%

Chitosan-Based Particulate Carriers: Structure, Production and Corresponding Controlled Release

2023

View full text Add to dashboard Cite

The state of the art in the use of chitosan (CS) for preparing particulate carriers for drug delivery applications is reviewed. After evidencing the scientific and commercial potentials of CS, the links between targeted controlled activity, the preparation process and the kinetics of release are detailed, focusing on two types of particulate carriers: matrix particles and capsules. More precisely, the relationship between the size/structure of CS-based particles as multifunctional delivery systems and drug release kinetics (models) is emphasized. The preparation method and conditions greatly influence particle structure and size, which affect release properties. Various techniques available for characterizing particle structural properties and size distribution are reviewed. CS particulate carriers with different structures can achieve various release patterns, including zero-order, multi-pulsed, and pulse-triggered. Mathematical models have an unavoidable role in understanding release mechanisms and their interrelationships. Moreover, models help identify the key structural characteristics, thus saving experimental time. Furthermore, by investigating the close relation between preparation process parameters and particulate structural characteristics as well as their effect on release properties, a novel “on-demand” strategy for the design of drug delivery devices may be developed. This reverse strategy involves designing the production process and the related particles’ structure based on the targeted release pattern.

show abstract

“…The natural dissolvable is removed to leave a pure dry mass. Next, the final choice is dispersed in water, and then a reasonable amount of salt is added to help the surfactant (6,7). We see a very small nanoparticle and use natural solvents to dissolve it (8).…”

Section: Reverse Micellar Methodmentioning

confidence: 99%

Chitosan Nanoparticle And Its Application In Non- Parenteral Drug Delivery

Patel¹,

Rawal²,

Patani³

2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

This study's main goals are to give an overview of chitosan-based nanoparticles used in a variety of non-parenteral applications and to call attention to new research on mucoadhesive and sustained release chitosan dosage forms. Chitosan is a biodegradable, biocompatible polymer that has been certified for use in wound dressings and is suitable for inclusion in human diets. For a variety of drug delivery methods, chitosan has been employed as a drug carrier in polymeric nanoparticles. Chitosan is a polymer with numerous possible uses since it has chemical functional groups that can be altered to serve particular purposes. The positive surface charges and mucoadhesive qualities of nanoparticles (np) made of chitosan and chitosan derivatives enable them to stick to mucous membranes and gradually release the therapeutic payload. This review will include examples of non-parenteral drug delivery techniques for treating eye infections, cancer, gastrointestinal disorders, pulmonary disorders, and cancer. Both in vitro and a few in vivo investigations show that chitosan has a low level of toxicity. This review looks at recent investigations on the characteristics, modifications, toxicity, pharmacokinetics, and preclinical trials of nanoparticles (np) made of chitosan for non-parenteral drug delivery.

show abstract

Exploring the effect of formulation parameters on the particle size of carboxymethyl chitosan nanoparticles prepared via reverse micellar crosslinking

Cited by 20 publications

References 49 publications

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

Chitosan-Based Particulate Carriers: Structure, Production and Corresponding Controlled Release

Chitosan Nanoparticle And Its Application In Non- Parenteral Drug Delivery

Contact Info

Product

Resources

About